The Hong Kong market has grown tremendously over the past three years with the launch of Hong Kong Exchange’s new regime to accept pre-revenue biotech companies, new economy companies and companies with weighted voting rights to list in 2018. New economy companies raised over 60% of IPO funds raised on HKEX over the past three years.
Hong Kong has become the first largest fund raising platform for healthcare and biotech companies in the world after the US market with over 30 pre-revenue biotech companies listed under the new Chapter 18A of the Listing Rules. PwC is proud to have 10 clients which have been successfully listed and raised a total of HKD 23.8b. And 25 clients have submitted their applications as at 30 September 2021.
PwC Hong Kong & Mainland China is launching our first Listing Guide for Biotech Companies which highlights the listing framework for listing on HKEX and the Mainland China A-share market.